Get the Stockscreener App
0.00
100.00%
-0.2071
After Hours:
.13
0.13
+
Renalytix Plc Adr stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
See More
Previous Close:
$0.2071
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$17.18M
Revenue:
$2.41M
Net Income/Loss:
$-42.50M
P/E Ratio:
0.00
EPS:
-0.9
Net Cash Flow:
$-36.15M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$2.40
Renalytix Plc Adr Stock (RNLX) Company Profile
Name
Renalytix Plc Adr
Sector
Industry
Phone
44 29 2071 0570
Address
FINSGATE, LONDON
Compare RNLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNLX
Renalytix Plc Adr
|
0.00 | 17.18M | 2.41M | -42.50M | -36.15M | -0.90 |
|
VEEV
Veeva Systems Inc
|
233.38 | 37.89B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
74.61 | 12.89B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
58.75 | 10.97B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
61.85 | 9.74B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
111.97 | 9.70B | 1.15B | 96.70M | -161.99M | 1.09 |
Renalytix Plc Adr Stock (RNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-18-22 | Initiated | H.C. Wainwright | Buy |
| Jan-04-22 | Initiated | BTIG Research | Buy |
| Oct-04-21 | Initiated | Guggenheim | Buy |
| Jul-02-21 | Initiated | Berenberg | Buy |
| Aug-11-20 | Initiated | Stifel | Buy |
Renalytix Plc Adr Stock (RNLX) Latest News
Renalytix restructures option plan for top management - Investing.com
Renalytix executives engage in share transactions - Investing.com
Stock Market Recap: Renalytix Plc ADR (RNLX) Concludes at 0.21, a 5.66 Surge/Decline - The Dwinnex
Commencement of trading on OTCQB in the United States - StockTitan
What was Renalytix Plc ADR (RNLX)’s performance in the last session? - US Post News
Renalytix Plc ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle
Ratios in Focus: Analyzing Renalytix Plc ADR (RNLX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Renalytix AI stock hits 52-week low at $0.22 amid market challenges - Investing.com
Renalytix Plc ADR (RNLX)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
There is no way Renalytix Plc ADR (RNLX) can keep these numbers up - SETE News
How analysts predict Renalytix Plc ADR (RNLX) will perform this quarter? - US Post News
Renalytix Plc ADR (RNLX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Investor’s Delight: Renalytix Plc ADR (RNLX) Closes Strong at 0.31, Up 7.31 - The Dwinnex
Renalytix Plc ADR (RNLX) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Analyzing RNLX’s price-to-book ratio for the last quarter - US Post News
Renalytix Plc ADR (RNLX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Closing Figures: Renalytix Plc ADR (RNLX)’s Negative Finish at 0.31, Down -23.14 - The Dwinnex
Form 8.5 (EPT/RI)-Renalytix Plc - GlobeNewswire Inc.
Investing in Renalytix Plc ADR (RNLX) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Examining Renalytix Plc ADR (RNLX) more closely is necessary - US Post News
Renalytix AI shares hold buy rating from HC Wainwright - Investing.com
Renalytix Partners with Steno for Kidney Care in Europe - Investing.com
Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination - Yahoo Finance UK
Renalytix faces delisting from Nasdaq over noncompliance - Investing.com
Medicare sets $950 price for Renalytix kidney test - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Investing.com South Africa
Fragrant Prosperity slumps as reverse takeover falls through - Proactive Investors USA
Renalytix Plc Adr Stock (RNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.99%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):